Lannett, a Philadelphia-headquartered generic drug manufacturer, has announced that it will invest $50 million to expand the facilities of Cody Laboratories, its Cody, Wyoming-headquartered wholly owned subsidiary and a manufacturer of active pharmaceutical ingredients (APIs) and finished dosage forms of pain-relief medications.

The expansion includes construction of five new buildings: one a controlled substances manufacturing plant and the other four for utilities, warehousing, and administration, according to a Lannett spokesperson. The five new buildings will be housed on a drug production campus in Cody’s North Industrial Park.

Cody Laboratories specializes in controlled substances API production. The company holds an import license granted in 2008 to import raw opiate material. This allows Cody Laboratories to manufacture APIs directly from plant extracts and to provide the APIs required to produce finished dosage forms.

As part of Lannett’s $50-million investment to expand the Cody Laboratories facilities, 45 new positions will be created in the town of Cody, Wyoming. Construction on the site is expected to start in spring 2017 and to be completed in the third quarter of 2018. Commercial operations are expected to begin by the end of 2020.

Source: Lannett